Company intelligence / Profile preview
PDRadiopharma Inc.
Sapporo, Hokkaido, Japanpdradiopharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
PDRadiopharma currently commercializes 24 diagnostic and 8 therapeutic products in Japan and is developing new radiopharmaceuticals including PD-32766 for renal cell carcinoma
- Therapeutic areas
- OncologyCardiovascularRheumatologyNeurology
- Modalities
- RadiopharmaceuticalsDiagnostic radiopharmaceuticalsTherapeutic radiopharmaceuticalsRadionuclide Drug Conjugates (RDC)Peptide-radionuclide conjugates (RI-PDC)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
NorthStar Medical RadioisotopesCuriumPeptiDream Inc.
Beyond the preview
Go deeper on PDRadiopharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDRadiopharma Inc..